MX380519B - Métodos, kits y aparato para expandir una población de células. - Google Patents

Métodos, kits y aparato para expandir una población de células.

Info

Publication number
MX380519B
MX380519B MX2016013493A MX2016013493A MX380519B MX 380519 B MX380519 B MX 380519B MX 2016013493 A MX2016013493 A MX 2016013493A MX 2016013493 A MX2016013493 A MX 2016013493A MX 380519 B MX380519 B MX 380519B
Authority
MX
Mexico
Prior art keywords
expanding
cells
kits
methods
cell population
Prior art date
Application number
MX2016013493A
Other languages
English (en)
Spanish (es)
Other versions
MX2016013493A (es
Inventor
Christian Stemberger
Lothar Germeroth
Original Assignee
Juno Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Gmbh filed Critical Juno Therapeutics Gmbh
Publication of MX2016013493A publication Critical patent/MX2016013493A/es
Publication of MX380519B publication Critical patent/MX380519B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/48Automatic or computerized control
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02Separating microorganisms from the culture medium; Concentration of biomass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12Purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0635B lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/52CD40, CD40-ligand (CD154)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/599Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2537/00Supports and/or coatings for cell culture characterised by physical or chemical treatment
    • C12N2537/10Cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Sustainable Development (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Computer Hardware Design (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
MX2016013493A 2014-04-16 2015-04-16 Métodos, kits y aparato para expandir una población de células. MX380519B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980506P 2014-04-16 2014-04-16
PCT/EP2015/058339 WO2015158868A2 (en) 2014-04-16 2015-04-16 Methods, kits and apparatus for expanding a population of cells

Publications (2)

Publication Number Publication Date
MX2016013493A MX2016013493A (es) 2017-05-10
MX380519B true MX380519B (es) 2025-03-12

Family

ID=53052805

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013493A MX380519B (es) 2014-04-16 2015-04-16 Métodos, kits y aparato para expandir una población de células.
MX2020014089A MX2020014089A (es) 2014-04-16 2016-10-13 Metodos, kits y aparato para expandir una poblacion de celulas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020014089A MX2020014089A (es) 2014-04-16 2016-10-13 Metodos, kits y aparato para expandir una poblacion de celulas.

Country Status (27)

Country Link
US (2) US11274278B2 (enExample)
EP (2) EP3132247B1 (enExample)
JP (4) JP6696969B2 (enExample)
KR (2) KR102459384B1 (enExample)
CN (3) CN111961647A (enExample)
AU (2) AU2015248786B2 (enExample)
BR (1) BR112016024072B1 (enExample)
CA (2) CA2945889C (enExample)
CY (1) CY1124717T1 (enExample)
DK (1) DK3132247T3 (enExample)
ES (1) ES2892927T3 (enExample)
HR (1) HRP20211430T1 (enExample)
HU (1) HUE056852T2 (enExample)
IL (3) IL293587B2 (enExample)
LT (1) LT3132247T (enExample)
MX (2) MX380519B (enExample)
MY (1) MY184699A (enExample)
PH (2) PH12016502017B1 (enExample)
PL (1) PL3132247T3 (enExample)
PT (1) PT3132247T (enExample)
RS (1) RS62471B1 (enExample)
RU (2) RU2020133435A (enExample)
SA (3) SA516380090B1 (enExample)
SG (2) SG11201608557UA (enExample)
SI (1) SI3132247T1 (enExample)
SM (1) SMT202100600T1 (enExample)
WO (1) WO2015158868A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
SI3132247T1 (sl) * 2014-04-16 2021-12-31 Juno Therapeutics Gmbh Postopki, kompleti in naprava za povečanje populacije celic
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
AU2016341529B2 (en) * 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
CN107129988A (zh) * 2016-02-29 2017-09-05 广西医科大学 一种特异性结合cd3的核酸适配体及其筛选方法和应用
EP3464608A4 (en) * 2016-06-02 2020-01-29 Klotho Therapeutics, Inc. THERAPEUTIC RECOMBINANT KLOTHO PROTEINS, COMPOSITIONS AND METHODS THEREFOR
JP7062640B2 (ja) 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗cd19抗体に対する抗イディオタイプ抗体
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
KR20190098747A (ko) * 2016-12-05 2019-08-22 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료법을 위한 조작된 세포의 제조방법
US12234441B2 (en) * 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) * 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) * 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7339160B2 (ja) * 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
US11891426B2 (en) * 2017-12-15 2024-02-06 Aleta Biotherapeutics Inc. CD19 variants
CN107904278B (zh) * 2017-12-25 2021-07-20 北昊干细胞与再生医学研究院有限公司 检测药物对细胞增殖影响的方法
US11149244B2 (en) * 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
EP3790958A1 (en) * 2018-05-08 2021-03-17 Life Technologies Corporation Compositions and methods for culturing and expanding cells
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
US12516099B2 (en) * 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
JP7495409B2 (ja) 2018-09-11 2024-06-04 ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ 改善された抗flt3抗原結合タンパク質
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
JP7376576B2 (ja) * 2018-09-24 2023-11-08 サウスウェスト リサーチ インスティテュート 三次元バイオリアクター
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
KR20200132147A (ko) * 2019-05-15 2020-11-25 의료법인 성광의료재단 자연 살해 세포의 배양용 조성물 및 이를 이용한 방법
CN114127561A (zh) * 2019-05-24 2022-03-01 索尔生物公司 使用开关样结合反应的亲和分离系统和方法
CN114207136A (zh) * 2019-06-07 2022-03-18 朱诺治疗学股份有限公司 自动化t细胞培养
KR20220101641A (ko) 2019-10-30 2022-07-19 주노 테라퓨틱스 게엠베하 세포 선택 및/또는 자극 장치 및 사용 방법
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
CN115916817A (zh) 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
EP4069742A1 (en) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2021152178A1 (en) 2020-01-31 2021-08-05 Cell.Copedia GmbH Methods of isolating a biological entity
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
IL295384B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
EP4192868A1 (en) 2020-08-05 2023-06-14 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
AU2022241654A1 (en) 2021-03-22 2023-09-28 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
EP4373920A1 (en) 2021-07-19 2024-05-29 Repairon Immuno GmbH Method of producing a population of immune cells from pluripotent stem cells
WO2023072006A1 (zh) * 2021-10-25 2023-05-04 黄�俊 多聚体在car表达细胞检测和细胞制备中的应用
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
JP2026504491A (ja) 2023-02-03 2026-02-05 ツェー3エス2 ゲーエムベーハー 操作された免疫細胞の非ウイルス的製造のための方法
CN121127253A (zh) 2023-02-28 2025-12-12 朱诺治疗学股份有限公司 治疗系统性自身免疫性疾病的细胞疗法
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
KR20260026101A (ko) 2023-05-23 2026-02-25 주노 쎄러퓨티크스 인코퍼레이티드 T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
CN117448255B (zh) * 2023-09-28 2024-12-31 深圳市龙华区人民医院 S2饲养细胞、制备方法及其应用
WO2025109111A1 (en) * 2023-11-22 2025-05-30 Immudex Aps Immune cell activating multimers
KR102824339B1 (ko) * 2024-07-01 2025-06-26 현대자동차주식회사 배터리 제어 장치 및 그 방법
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
EP0198015B2 (en) 1984-10-02 1995-07-19 Biogen, Inc. Production of streptavidin-like polypeptides
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
ATE293686T1 (de) 1993-06-04 2005-05-15 Us Navy Verfahren zur selektiven stimulierung der t- zellproliferation.
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
AU708375B2 (en) 1995-02-09 1999-08-05 University Of Washington Modified-affinity streptavidin
US6022951A (en) 1995-04-11 2000-02-08 Univ Boston Streptavidin mutants
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
EP0977770A4 (en) 1997-03-14 2000-04-05 Univ Boston DIFFERENTLY FLAVORED STREPTAVIDINE
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
US6664042B1 (en) 1999-01-26 2003-12-16 Cornell Research Foundation, Inc. Determining viral load in double negative T cells
AU773954B2 (en) * 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
BR0009403A (pt) 1999-02-04 2001-11-27 Technion Res & Dev Foundation Método de expansão/conservação das células detronco hemopoiéticas indiferenciadas ou dascélulas progenitoras, método de preparação deum meio condicionado de célula estomacal útil naexpansão/conservação das células de troncohemopoiéticas indiferenciadas ou das célulasprogenitoras, método de transplante de célulasde tronco hemopoiéticas indiferenciadas ou decélulas progenitoras em um recipiente, tampão debiorreator e biorreator
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
EP1630171B1 (de) 2002-03-01 2007-08-15 Volker A. Erdmann Streptavidin-Bindungspeptid
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
AU2003234194A1 (en) 2002-04-23 2003-11-10 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
EP2359689B1 (en) 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
SG150387A1 (en) 2003-05-02 2009-03-30 Insception Bioscience Inc Apparatus and methods for amplification of blood stem cell numbers
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
WO2005050209A1 (en) 2003-11-20 2005-06-02 Biosensor Applications Sweden (Publ) Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
US7776583B2 (en) 2004-06-03 2010-08-17 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
US20110098184A1 (en) 2004-10-15 2011-04-28 Day Anthony G Competitve differntial screeing
WO2006058226A2 (en) * 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US7704708B2 (en) * 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2007117602A2 (en) 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation and use of human regulatory t cells
US20070238169A1 (en) * 2006-04-11 2007-10-11 The Board Of Trustees Of The Leland Stanford Junior University Cell sorter and culture system
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
KR101543622B1 (ko) 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Mphosph1 또는 depdc1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
US8043822B2 (en) 2006-11-02 2011-10-25 Kyowa Medex Co., Ltd. Method of immunoassaying a component to be measured
AU2007353319A1 (en) 2006-11-15 2008-11-20 Invitrogen Dynal As Methods for reversibly binding a biotin compound to a support
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
EP2617827A1 (en) * 2007-03-26 2013-07-24 Celexion, LLC Method for displaying engineered proteins on a cell surface
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
ES2445152T3 (es) 2007-08-20 2014-02-28 Nextera As Presentación en fagos de pVII
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
WO2009097119A2 (en) 2008-01-29 2009-08-06 Fred Hutchinson Cancer Research Center Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
US20120214187A1 (en) * 2009-11-02 2012-08-23 Ffina Biolutions, Llc Method for Enhancing the Sensitivity of Antibody Based Assays
US20120321665A1 (en) * 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
EP2601521B1 (en) 2010-08-06 2018-05-02 Ludwig-Maximilians-Universität München Identification of t cell target antigens
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US9023604B2 (en) * 2011-07-18 2015-05-05 Iba Gmbh Method of reversibly staining a target cell
US9353161B2 (en) 2011-09-13 2016-05-31 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
ES3011307T3 (en) 2012-02-23 2025-04-07 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
UA114108C2 (uk) * 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
JP6482461B2 (ja) 2012-07-13 2019-03-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 投与に関する形質導入t細胞の適合性の評価方法
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
CN105073770B (zh) 2012-11-16 2019-08-06 Iba股份有限公司 链霉亲和素突变蛋白及其使用方法
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
SI3132247T1 (sl) 2014-04-16 2021-12-31 Juno Therapeutics Gmbh Postopki, kompleti in naprava za povečanje populacije celic
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CN106062185A (zh) 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
HUE049514T2 (hu) 2014-04-25 2020-09-28 Bluebird Bio Inc Javított eljárások adoptív sejtterápiák kialakítására
US11150239B2 (en) * 2014-04-30 2021-10-19 Iba Lifesciences Gmbh Method of isolating a target cell
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
EP3365453A2 (en) 2015-10-22 2018-08-29 Juno Therapeutics GmbH Methods, kits, agents and apparatuses for transduction
EP4212547A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same

Also Published As

Publication number Publication date
MX2020014089A (es) 2021-07-21
CA2945889C (en) 2024-01-09
JP6696969B2 (ja) 2020-05-20
EP3988920A1 (en) 2022-04-27
CN106414724A (zh) 2017-02-15
CN116656605A (zh) 2023-08-29
SA521421882B1 (ar) 2023-11-19
US20170037368A1 (en) 2017-02-09
RS62471B1 (sr) 2021-11-30
SMT202100600T1 (it) 2021-11-12
PH12016502017A1 (en) 2017-01-09
EP3132247B1 (en) 2021-08-18
PL3132247T3 (pl) 2022-01-03
RU2020133435A (ru) 2020-12-01
PH12016502017B1 (en) 2017-01-09
AU2015248786A1 (en) 2016-11-03
JP2023062124A (ja) 2023-05-02
KR20170003932A (ko) 2017-01-10
NZ725213A (en) 2021-10-29
CA2945889A1 (en) 2015-10-22
PT3132247T (pt) 2021-11-03
RU2016144724A (ru) 2018-05-18
WO2015158868A3 (en) 2016-01-28
WO2015158868A2 (en) 2015-10-22
CA3176848A1 (en) 2015-10-22
RU2735640C2 (ru) 2020-11-05
AU2015248786B2 (en) 2021-11-04
NZ763583A (en) 2021-10-29
MX2016013493A (es) 2017-05-10
IL293587B1 (en) 2024-10-01
AU2022200527A1 (en) 2022-02-17
IL280738B (en) 2022-07-01
EP3132247A2 (en) 2017-02-22
BR112016024072B1 (pt) 2021-02-09
DK3132247T3 (da) 2021-10-11
RU2016144724A3 (enExample) 2018-12-12
MY184699A (en) 2021-04-18
PH12020551028A1 (en) 2021-06-07
SA520412247B1 (ar) 2023-12-05
LT3132247T (lt) 2021-12-10
SG11201608557UA (en) 2016-11-29
KR20220150988A (ko) 2022-11-11
SI3132247T1 (sl) 2021-12-31
IL280738A (en) 2021-03-25
KR102459384B1 (ko) 2022-10-26
JP2020124210A (ja) 2020-08-20
IL248360B (en) 2021-02-28
BR112016024072A2 (pt) 2017-10-10
NZ763585A (en) 2021-10-29
IL293587B2 (en) 2025-02-01
JP2017513524A (ja) 2017-06-01
JP2025060756A (ja) 2025-04-10
SG10201808491UA (en) 2018-11-29
US20220195388A1 (en) 2022-06-23
SA516380090B1 (ar) 2021-10-21
JP7762499B2 (ja) 2025-10-30
IL293587A (en) 2022-08-01
NZ763587A (en) 2021-11-26
IL248360A0 (en) 2016-11-30
ES2892927T3 (es) 2022-02-07
KR102714469B1 (ko) 2024-10-11
HRP20211430T1 (hr) 2021-12-10
AU2022200527B2 (en) 2025-03-27
US11274278B2 (en) 2022-03-15
AU2022200527B9 (en) 2025-05-08
CN111961647A (zh) 2020-11-20
CY1124717T1 (el) 2022-07-22
RU2735640C9 (ru) 2021-02-08
HUE056852T2 (hu) 2022-03-28

Similar Documents

Publication Publication Date Title
PH12020551028A1 (en) Methods, kits and apparatus for expanding a population of cells
CL2016001867A1 (es) Sistema y dispositivo para la generación de alto rendimiento de gotitas y métodos de uso combinatorios.
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
EP3194577A4 (en) Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
GB2525104A (en) Massively parallel single cell analysis
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
EP4345460A3 (en) Assay apparatuses, methods and reagents
EP4684881A3 (en) Methods, systems, computer program and non-transitory computer-readable medium for in-pen assays
BR112014018995A2 (pt) Sistemas para executar ensaio automatizado
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
MX344792B (es) Sistemas y métodos para múltiples análisis.
PE20190229A1 (es) Anticuerpos anti-fcrn
MX382654B (es) Suministro selectivo de material a células.
EP4300100A3 (en) Reagent storage in an assay device
WO2014194131A3 (en) Systems and methods for sequencing in emulsion based microfluidics
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112017022329A2 (pt) métodos para detectar aglutinação e composições para uso na prática do mesmo
AU2013252445A8 (en) Assays, methods and apparatus for assessing RNA disruption
GB2542576A (en) Method and kit of detecting the absence of micro-oranisms
TR201907737T4 (tr) Test numunesi desteği ve çarpışma testi aparatı ve destek kullanılarak yapısal elemanın çarpışma testi yöntemi.
MX377788B (es) Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana.
MX2018004029A (es) Deteccion de analitos con multiples sustratos.
MY182547A (en) Polymerase chain reaction detection system
BR112017002575A2 (pt) método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo